@Article{Grabarczyk2024,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="111",
number="6",
year="2024",
title="Facial Pyoderma Gangrenosum – Presentation of Two Clinical Cases and Literature Review",
abstract="Pyoderma gangrenosum is a rare neutrophilic dermatosis characterized by a distinct clinical course and typical morphology of skin lesions. Most commonly, it affects the lower legs, while head and neck involvement is extremely rare. We present 2 cases of pyoderma gangrenosum manifesting on the face, with simultaneous exacerbation of inflammatory bowel disease. In the treatment regimen, anti-TNF-a inhibitors were administered alongside steroid therapy, leading to rapid remission of the skin lesions. Treatment with infliximab was associated with rapid remission of pyoderma gangrenosum and a reduction in the severity of the inflammatory process in the gastrointestinal tract. Infliximab is a highly effective option for managing facial pyoderma gangrenosum in patients with coexisting inflammatory bowel disease and should be considered as the first-line treatment. In the differential diagnosis of non-healing facial ulcers, pyoderma gangrenosum should be considered alongside neoplasms and granulomatosis with polyangiitis, particularly when the patient’s medical history suggests bowel disease.",
author="Grabarczyk, Małgorzata N.
and Zawadzińska-Halat, Kamila
and Smyk, Jolanta
and Pastuszczak, Maciej",
pages="429--434",
doi="10.5114/dr.2024.150242",
url="http://dx.doi.org/10.5114/dr.2024.150242"
}